Trial Profile
A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2019
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary) ; Dalcetrapib (Primary)
- Indications Atherosclerosis; Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia
- Focus Pharmacokinetics
- Sponsors Roche
- 01 Dec 2011 Actual end date changed from Sep 2011 to Oct 2011 as reported by ClinicalTrials.gov.
- 19 Sep 2011 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jun 2011 New trial record